Novartis: Rhapsido shows sustained symptom improvement over 52 weeks in chronic inducible urticaria
Novartis reports 52 weeks of sustained symptom improvement with Rhapsido in chronic inducible urticaria and plans to file additional approval applications.
Novartis said on Thursday evening that treatment with Rhapsido led to sustained symptom improvements over 52 weeks in patients with chronic inducible urticaria (CIndU), according to ad-hoc-news.de. ad-hoc-news.de
ad-hoc-news.dead-hoc-news.deOpen source ↗ The company stated that the safety profile was comparable to that seen in earlier studies in chronic spontaneous urticaria (CSU).
Rhapsido is already approved in many countries for the treatment of CSU. On the basis of the new data, Novartis intends to submit additional marketing authorization applications for the treatment of CIndU. The applications have not yet been submitted: the company only announced its intention to file them.
